Page last updated: 2024-09-05

organophosphonates and Stroke

organophosphonates has been researched along with Stroke in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bedimo, RJ; Drechsler, H; Tebas, P; Vidiella, G; Westfall, AO	1
De Keyser, J; Diener, HC; Elting, JW; Hommel, M; Kaste, M; Lees, KR; Sulter, GA; Teelken, AW; Versavel, M	1
De Keyser, J; Diener, HC; Hommel, M; Kaste, M; Lees, KR; Steiner, H; Versavel, M; Walters, MR	1

Trials

2 trial(s) available for organophosphonates and Stroke

Article	Year
AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke, 2002, Volume: 33, Issue:12 Topics: Acute Disease; Aged; Area Under Curve; Biomarkers; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nerve Growth Factors; Neuroglia; Organophosphonates; Phosphopyruvate Hydratase; Quinoxalines; Receptors, AMPA; Regression Analysis; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Severity of Illness Index; Stroke; Treatment Outcome	2002
The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovascular diseases (Basel, Switzerland), 2005, Volume: 20, Issue:5 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Electrocardiography; Humans; Middle Aged; Organophosphonates; Patient Compliance; Quinoxalines; Receptors, AMPA; Stroke; Treatment Outcome	2005

Article

Year

AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.

Stroke, 2002, Volume: 33, Issue:12

Topics: Acute Disease; Aged; Area Under Curve; Biomarkers; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nerve Growth Factors; Neuroglia; Organophosphonates; Phosphopyruvate Hydratase; Quinoxalines; Receptors, AMPA; Regression Analysis; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Severity of Illness Index; Stroke; Treatment Outcome

2002

The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study.

Cerebrovascular diseases (Basel, Switzerland), 2005, Volume: 20, Issue:5

Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Electrocardiography; Humans; Middle Aged; Organophosphonates; Patient Compliance; Quinoxalines; Receptors, AMPA; Stroke; Treatment Outcome

2005

Other Studies

1 other study(ies) available for organophosphonates and Stroke

Article	Year
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Jul-01, Volume: 53, Issue:1 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Infections; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Organophosphonates; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Tenofovir; United States; United States Department of Veterans Affairs	2011

Article

Year

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Jul-01, Volume: 53, Issue:1

Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Infections; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Organophosphonates; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Tenofovir; United States; United States Department of Veterans Affairs

2011